TheralinkTheralink

  • Theralink
    • The Theralink platform
    • The Theralink Assay
    • Request RPPA Analyte List
    • RPPA Clinical Publications
    • RPPA Research Publications
    • RPPA Technical Publications
  • About
    • Overview
    • Oncologists
    • Mission Statement
    • Management Team
    • Medical Advisory Board
    • Scientific Advisory Board
    • Board of Directors
  • News & Media
    • Press Releases
    • Media & Articles
    • Theralink Blog
  • Biopharmas
    • Overview
    • Explore Technology
    • Explore Targets
    • Explore Pathways
    • Request Pathway Quote
    • Conference Abstracts
    • FAQ
  • Investor Relations
    • Overview
    • Press Releases
    • Events & Presentations
    • Financial Information
    • Stock Information
    • Investor Resources
      • FAQ
      • Contacts Us
    • Corporate Governance
      • Management Team
      • Medical Advisory Board
      • Scientific Advisory Board
      • Board of Directors
  • Contacts

Financial Information

Theralink   →  Financial Information

Financial Information

FINANCIAL INFORMATION

SEC Filings

  • All SEC Filings
  • Annual Reports
  • Quarterly Reports
  • Section 16 Filings
DATE From DESCRIPTION DOCS XBRL
08/15/22 10-Q Quarterly report [Sections 13 or 15(d)]
07/11/22 8-K/A Current report: [Amend] - Item 5.03 Item 5.07 Item 9.01
07/07/22 8-K Current report - Item 5.03 Item 5.07 Item 9.01
06/22/22 4 Statement of changes in beneficial ownership of securities
06/21/22 3 Initial statement of beneficial ownership of securities
06/02/22 DEF 14C Other definitive information statements
05/23/22 10-Q Quarterly report [Sections 13 or 15(d)]
05/20/22 PRE 14C Other preliminary information statements
05/17/22 NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
04/05/22 8-K Current report - Item 5.02
  • << Previous
  • 1
  • ...
  • 2
  • 3
  • 4
  • 5
  • 6
  • ...
  • 20
  • Next >>

SEC Filings

  • All SEC Filings
  • Annual Reports
  • Quarterly Reports
  • Section 16 Filings
Theralink Technologies intends to be a market leader in precision medicine for more effective cancer treatments

Menu

  • About
  • Investors
  • Contact
  • Privacy Policy

OUR SERVICES

  • Biopharmas
  • Oncologists
  • Media Room

Press Releases

  • Theralink® Acquires Two New Milestone Patents Relating to Methods for Treating Breast Cancer
  • Theralink® Technologies to Host Fireside Chat with Dr. Mick Ruxin on June 22nd at 11:00 a.m. ET
  • Theralink® Technologies Expands Adoption of its Precision Medicine Technology in the Biopharmaceutical Industry
Copyright © 2022 Theralink. All rights reserved.